


Available online on 15.06.2020 at <http://ajprd.com>



Asian Journal of Pharmaceutical Research and Development

Open Access to Pharmaceutical and Medical Research

© 2013-20, publisher and licensee AJPRD, This is an Open Access article which permits unrestricted non-commercial use, provided the original work is properly cited



Open  Access

Review Article

Duchene Muscular Dystrophy: Pathogenesis, Pathophysiology, Diagnosis Management to Therapy.

Bharti Sharma¹, Savita Devi², Kamaldeep Singh^{1*}

¹School of Medical & Allied Sciences, Department of Medical Lab Technology, Galgotias University, Greater Noida, Uttar Pradesh.

²School of Paramedical and Physiotherapy, Department of Medical Laboratory Technology, Lovely Professional University, Punjab, India, 144411

ABSTRACT

Duchene muscular dystrophy (DMD) is a neuromuscular inherited disease which deal with X-linked occurs due to mutations in the dystrophin gene. The characterisation achieved by progressive muscle weakness in all our the body specially in legs and arms and wasting due to the absence of dystrophin protein which further causes degeneration of different types of muscles such as skeletal and cardiac. Gene mutation is one of the major causes for Duchenne muscular dystrophy located in cytoskeletal protein dystrophin. The diagnosis can be start up with careful review of the physical condition, history and examination of body organs and developmental delay, proximal weakness in muscles, and elevated biochemical compound serum creatine kinase, plus other confirmatory test like muscle biopsy or genetic testing. To improve the life expectancy of patient the early use of exercises, diet & nutrition management and other supportive strategies has been implemented. Moreover, uncontrolled condition can be treated with gene therapy with the use of plasmids or viruses, mutations and short DNA fragments can be corrected, oligonucleotides are first line treatment for exon skipping of mutations. Myoblasts or stem cells replacement therapy can be apply to reproduction of muscles.

KEYWORDS: Duchene muscular dystrophy, dystropin, gene mutation, muscles wasting and stem cell.

ARTICLE INFO: Received 27 March 2020; Review Completed 12 May 2020; Accepted 27 May 2020; Available online 15 June. 2020



Cite this article as:

Sharma B, Devi S, Singh K, Duchene Muscular Dystrophy: Pathogenesis, Pathophysiology, Diagnosis Management to Therapy, Asian Journal of Pharmaceutical Research and Development. 2020; 8(3):130-134.

DOI: <http://dx.doi.org/10.22270/ajprd.v8i3.733>

*Address for Correspondence:

Kamaldeep Singh, School of Medical & Allied Sciences, Department of Medical Lab Technology, Galgotias University, Greater Noida, Uttar Pradesh

INTRODUCTION

DMD is a disease which currently affecting 1 in 3600-6,000 in newborn baby (boy) associated with X-chromosome. Disease firstly characterized by weakness in the muscles. It is abnormal gait so it's indicating through positive Gowers sign.¹ Similar symptoms also seen in calf muscle disorder (posterior compartment of leg) and examined by the serum creatinine kinase level. Generally DMD disease patient show effects around in 5-6 years of age and after this year symptoms become more severe. DMD has been mostly affect on cardiac muscles or Respiratory systems but its effect commonly watched in boys.^{2,3} After 13 years of age patient usually stopped walking and if condition is not treat on time then both cardiac system and Respiratory system get infected and dysfunction. (1,2). DMD is a genetically and

muscular atrophy progressive disease. Prevalence of diseases estimate in population is 1.8-4.8per 100,000.^{4,5}

DMD is mostly common observe in childhood age of patient. However, found in new born baby also and abnormalities are attached with X-chromosomes. Generally cause by mutation in the protein specifically at X - chromosomes on dystrophin gene.⁶ Dystophhin is a rod shaped cytoplasm protein. Present within innar surface area of muscle membrane. Some symptoms like delayed the speech, patient never running properly, weakness of hip, shoulder gridles muscle lead and pseduohypertroph of calf muscle in this disease.⁷

DMD & BMD both are mostly common inherited and neuromuscular disease and denoted with gene expressed by Xp21. Dystophhin gene deletatin are found in 55%of patient with BMD and 65% of Patients of DMD,

respectively.⁸ Identification carried by performing Genetic testing through PCR (polymerase reaction) and other Dystrophin level estimated tests.⁹ Muscle biopsy demonstrates the degenerating muscle fibers are present in the form of clusters. These necrotic fibers placed nearby macrophages and another one is CD4 lymphocytes cells.¹⁰ Figure 3.

CAUSES

Duchenne muscular dystrophy is caused by completely absence of dystrophin protein in muscle and found in sarcolemma of muscle fibers and it's divided in 4 parts i.e. The C-terminal domain- it's common for joints others proteins in membrane it's called the dystroglycan complex, The Rod domain, The Cysteine rich domain and N terminal domain.^{11,12} These all types of domains bind with actin and postulated that dystrophin is essential to transduce of the contractile required to outside of cell matrix. Additionally, DMD caused by muscle fibers or completely absence of cytoplasm protein and further lead to damage to mechanical scleroma or loss of calcium level in body or loss of the muscle fibers.^{13,14}




Figure 1: Numbers of theory which further develops DMD in patient.

PATHOGENESIS:-

There are mainly three types of theories for define the pathogenesis of Duchenne muscular Dystrophy. The cumulative evidence suggested that abnormal microvascular and muscle surface is mostly common but not yet proven.

The vascular theory –

Firstly in 1996 a theory revived and suggested that adequate blood flow might account for generation of Dystrophy muscle. Found that slowed circulation in arm to tongue in patients can occur by Duchenne muscular Dystrophy.¹⁵ (As per figure 1) Some new suggestion that abnormalities of catecholamine metabolism due to oxidation in platelets and platelets report showing abnormal and uptake serotonin also. In fluorescence observe the dystrophy muscles accumulation of catecholamine observe by cerescopy. Other examination depicts Muscle lesions, ischemia at chronic stage.¹⁶

The Neurogenic Theory

The muscle Dystrophy pathogenesis firstly cleared within last half in 19th century. Some other patient with DMD disease went from post-mortem pathology and there report shows burnt of anatomical changes in spinal cord which reveal the “spinal muscle Atrophy”.¹⁷ The dystrophies was separate by another myopathies the basis of heritable transmission. Regarding these all reasons Neurogenic theories to be fading but this type of issue in not closed.¹⁸ In muscle dystrophies generally affected on metabolic

disorder of hypothyroidism of spinal cord in the deficiency of vitamin B12 and then cause the pernicious anemia, this principle also cleared at the same time.¹⁹

Membrane and muscle disease

These both types of theories (Neurogenic and vascular) is still required some special technique to understand pathogenesis and to perform other biomedical tests and genetics test to clear the concept.^{20,21} These type of different technique identify the abnormalities occurs in biochemical changes and all genetic problems related to protein abnormality. DMD genetic disease are caused due to an anomalous protein or abnormality of protein in side our body.^{22,23}

Duchenne Dystrophy

Previous observation recognized abnormality of biochemical in Duchenne Dystrophy increased excretion of creatinine, there was no overt abnormality of metabolic patterns within muscle. So mechanism of the abnormality not fully elucidated. Suggest that there is decrease value of creatinine in muscle with degenerative condition such as amyotrophic lateral sclerosis but there is impaired “trapping” inside the cells compound in Dystrophy muscle.²⁴⁻²⁶ In DMD serum enzymes and proteins arise from muscle which further increased serum activity and decreased in muscle.²⁷




Figure 2: List of path physiological reasons to cause DMD diseases.

PATHOPHYSIOLOGY

Muscle fiber Necrosis:-

Mechanical Hypothesis- Early estimation of muscle Dystrophy (as Delta lessons) and decreased level of muscle enzymes in DMD patient with sample of muscle fibers.²⁸ Dystrophin is a type of protein present in muscles in the form of protein complex. (Figure 2) In view of absence, any one type of protein in muscle leads to muscle membrane loss integrity of the fibers. This research has led to the emergence of the exercise and important implications for managed.²⁹⁻³¹

Calcium Hypothesis:-

Certainly, it is a critical aspects of muscle function documentation of calcium accumulation and fibers in muscle Biopsies of DMD patients. As concern with pathophysiology, the increase influx of deficiency of Dystrophin membrane has been demonstrate in DMD patient.^{32,33}

Vascular Hypothesis:-

DMD is early affected in clusters and necrotic fiber's play important role of the Muscle vasculature in pathophysiologic hypotheses postulated. However structural studies have revealed no blood vessel malaties observed.^{34,35} Nitric oxide is present in skeleton muscle and production started in muscle cells by the isoform which

leads to floating freely in cytoplasm and slowly reduced.^{36,37}

Gene Regulation Hypothesis:-

Play vital role in membrane stabilization and in DMD involved the complex of protein and in other process such as mechanism of transduction muscle activity related gene expression.³⁸ Dystrophin associated and make the complex related to absence of Dystrophin proteins result in various genes. Interestingly the injection of stem cells into Dystrophin deficiency muscle is not only partially dystrophin protein complex but also restores physiology gene expression.³⁹

Tissue Remodeling:-

Tissue remodelling based on the several observation and put emphasis on secondary features of Dystrophin deficiency, for instant – Null mutation of Dystrophin produce early onset action like progressiveness of disease in body.^{40,41} (Figure 2) For DMD treatment anabolic steroids counted as good since it protecting muscle mass. Other medicines like Methandrostenolone or Norethandrolone cause initial gives modest improvements but accompanied by androgenic side effects.^{42,43}

Inflammatory Hypothesis:-

In DMD patients consistently exhibit inflammatory changes in muscles. That cases activities the numerous components of chronic inflammatory response including cytokine and cytokine signaling, Leukocyte adhesion, cell types specific markers and complement system activation.⁴⁴⁻⁴⁶ In DMD most commonly used drug is corticosteroids and provide the anti inflammatory effects. Deflazacort an oxazoline derivate of drednisolone, these also give similar effect but with observing loss in weight gain.⁴⁷

Diagnosis, Management and Treatment:-

DMD diagnosed of care and provide an accurate and prompt diagnosis, allow the initiation and appropriate interventions continuing support and education and minimize the length. Diagnosis should be done by neuromuscular specialist. Mention all parameters in figure no. should be followed to diagnose the disease. Similarly many points are there to manage and treatment of DMD also given to cure this disorder.⁴⁸⁻⁵⁰



Figure 3: The table depicts the possible diagnosis for DMD disease, the various parameters need to follow before comes to any conclusion of result. Further, the different ways to taken as a part of management of disease which have lists of techniques to provide relaxation of symptoms and management of DMD. At the last the different approaches to cure the DMD somehow cannot cure the diseases completely but initial diagnosis can help to reduce the further development of disease in body.

CONCLUSION

Early recognition and precise genetic diagnosis will allow for individualized therapeutic options for DMD. Even though there is presently no cure, respiratory intervention and other supportive strategies as outlined in the current standard of care for DMD have led to improved survival and better health-related quality of life for many affected individuals. New emerging treatments will depend on the appropriate use of clinical end points and sensitive surrogate outcome measures such as muscle MRI and circulating biomarkers to detect meaningful changes in disease progression.

REFERENCES:-

- Gorospe JR, Hoff man EP. Duchene muscular dystrophy. *Curr Opin Rheumatol* 1992; 4:794–800
- Ishikawa Y, Miura T, Ishikawa Y, et al. Duchene muscular dystrophy: survival by cardio-respiratory interventions. *Neuromuscul*; 21:47–51.
- Demos J: Platelet diphenoloxidase in progressive muscular dystrophy. *Clin Genet*, 1973; 4:79-90.
- Pacold I, Morgan J, Cohen L: Absence of differences in platelet dihydroxyphenylalanine oxidase polymorphism in health and Duchenne's muscular dystrophy. *Clin Genet*, 1975; 7:435-441.
- Murphy DL, Mendell JR, Engel WK: Serotonin and platelet function in Duchenne muscular dystrophy. *Arch neurol*, 1973; 28:239-241.
- Wright TL, O'Neill JA, Olson WH: Abnormal intrafibrillar monamines in sex-linked muscular dystrophy. *Neurology*, 1973; 23:510-517.
- Karpati G, Carpenter SM: Experimental ischemic myopathy. *J Neurol Sci*, 1974; 23:129-161.
- Bradley WG, O'Brien MD, Walder DN, et al: Failure to confirm a vascular cause of muscular dystrophy. *Arch Neurol*. 1975; 32:466-473.
- Jerusalem F, Engel AG, Gomez MR: Duchenne dystrophy: Morphometric study of the muscle microvasculature. *Brain*, 1974; 97:115-122.
- Mendell JR, Murply DL, Engel WK: Catecholamines and indoleamines in patients with Duchenne muscular dystrophy. *Arch Neurol*, 1972; 27:518-520.
- Swash M, Fox KP, Davidson AR: Carcinoid myopathy: Serotonin-induced muscle weakness in man? *Arch Neurol*, 1975; 32:572-574.
- Rowland LP: Are the muscular dystrophies neurogenic? *Ann NY Acad Sci*, 1974; 228:244-260.
- Buller A, Eccles JC, Eccles RM: Interactions between motoneurons and muscles in respect of the characteristic speeds of their responses. *J Physiol*, 1960; 150:417-439.
- Karpati G, Carpenter SM: Experimental ischemic myopathy. *J Neurol Sci*, 1974; 23:129-161.
- Miike T, Sugino S, Ohtani Y, Taku K, Yoshioka K. Vascular endothelial cell injury and platelet embolism in Duchenne muscular dystrophy at the preclinical stage. *J Neurol Sci* 1987; 82:67-80.
- Petrof BJ, Shrager JB, Stedman HH, Kelly AM, Sweeney HL. Dystrophin projects the sarcolemma from stresses developed during muscle contraction. *Proc Natl Acad Sci USA* 1993; 90:3710-4.
- Lacomis D. The use of percutaneous needle muscle biopsy in the diagnosis of myopathy. *Curr Rheumatol Rep* 2000; 2:225–29.
- Lacomis D. The utility of muscle biopsy. *Curr Neurol Neurosci Rep* 2004; 4:81–86.
- Tzeng AC, Bach JR. Prevention of pulmonary morbidity for patients with neuromuscular disease. *Chest* 2000; 118:1390–96.
- Fitch CD, Lucy DD, Bornhofen JH, et al: Creatine metabolism in skeletal muscle: III. nCreatine kinetics in man. *Neurology*, 1968; 18:32-42.
- Sibley JA, Lehninger AL: Aldolase in serum and tissues of tumor-bearing animals. *J Natl Cancer Inst* 1949; 9:303-309.
- Somer H, Donner M, Murros J, et al: Serum isozyme study in muscular dystrophy: Particular reference to creatine kinase, aspartate aminotransferase, and lactic acid dehydrogenase isozymes. *Arch Neurol* 1973; 29:343-345.
- Mokri B, Engel AG. Duchenne dystrophy: Electron microscopic findings pointing to a basic or early abnormality in the plasma membrane of the muscle fiber. *Neurology* 1975; 25:1111-20
- Mosns P, Baatsen PH, Marechal Increased susceptibility of EDL muscles from mdx mice to damage induced by contractions with stretch. *J Muscle Res Cell Motil* 1993; 14:446-51.
- Deconinck N, Ragot T, Maréchal G, Perricaudet M, Gillis JM. Functional protection of dystrophic mouse (mdx) muscles after adenovirus-mediated transfer of the mindystrophin gene. *Proc Natl Acad Sci USA* 1996; 93:3570-4
- Deconinck N, Tinsley JM, Kahn D, et al. Expression of full length utrophin prevents muscular dystrophy in mdx mice. *Nat Med* 1998; 14:1441-45.
- De Bari C, Dell'Accio F, Vandennebee F, Vermeesch JR, Raymackers JM, Luyten FP. Skeletal muscle repair by adult human mesenchymal stem cells from synovial membrane. *J Cell Biol* 2003; 160:909-18.
- Cooper BJ. Animals models of Duchenne and Becker muscular dystrophy. *Br Med Bull* 1989; 45:703-18.
- Yilmaz O, Karaduman A, Topaloglu H. Prednisolone therapy in Duchenne muscular dystrophy prolongs ambulation and prevents scoliosis. *Eur J Neurol* 2004; 11:541-4.
- Biggar WD, Politano L, Harris VA, et al. Deflazacort in Duchenne muscular dystrophy: A comparison of two different protocols. *Neuromuscular Disord* 2004; 14:476-82.
- Parsons, EP, Clark AJ, Bradley DM. Developmental progress in Duchenne muscular dystrophy: lessons for earlier detection. *Eur J Paediatr Neurol* 2004; 8: 145–53.
- Berchtold MW, Brinkmeier H, Muntener M. Calcium ion in skeletal muscle: Its crucial role for muscle function, plasticity, and disease. *Physiol Rev* 2000; 80:1215-65.
- Bodensteiner JB, Engel AG. Intracellular calcium accumulation in Duchenne dystrophy and other myopathies: A study of 567,000 muscles fibers in 114 biopsies. *Neurology* 1978; 28:439-46.
- Cullen MJ, Fulthorpe JJ. Stages in fibre breakdown in Duchenne muscular dystrophy: An electron-microscopic study. *J Neurol Sci* 1975; 24:179-200.
- Duncan CJ. Role of intracellular calcium in promoting muscle damage: A strategy for controlling the dystrophic condition. *Experientia* 1978; 34:1531-5.
- Kobzik L, Reid MB, Bredt DS, Stamler JS. Nitric oxide in skeletal muscle. *Nature* 1994; 372:564-8.
- Bren man JE, Chao DS, Xia H, Aldape K, Bredt DS. Nitric oxide synthase complexed with dystrophin and absent from skeletal muscle sarcolemma in Duchenne muscular dystrophy. *Cell* 1995; 82:734-52.
- Crosbie RH, Barresi R, Campbell KP. Loss of sarcolemma n-NOS in sarcoglycan-deficient muscle. *FASEB* 2002; 16:1786-91.
- HaslettHaslett JN, Sanoudou D, Kho AT, et al. Gene expression comparison of biopsies from Duchenne muscular dystrophy (DMD) and normal skeletal muscle. *Proc Natl Acad Sci USA* 2002; 99:15000-5.
- Spencer MJ, Montecino-Rodriguez E, Dorshkind K, Tidball JG. Helper (CD4) and cytotoxic (CD8) T cells promote the pathology of dystrophin-deficient muscle. *Clin Immunol* 2001; 98:235-43.
- Muntoni F. Is a muscle biopsy in Duchenne dystrophy really necessary? *Neurology* 2001; 57:57475
- Matsumura K, Ohlendieck K, Ionasescu VV, et al. The role of the dystrophin-glycoprotein complex in the molecular pathogenesis of muscular dystrophies. *Neuromuscul Disord* 1993; 3:533–35.

43. Sutherland DH, Olshen R, Cooper L, et al. The pathomechanics of gait in Duchenne muscular dystrophy. *Dev Med Child Neurol* 1981; 23:3–22.
44. Siegel IM. Pathomechanics of stance in Duchenne muscular dystrophy. *Arch Phys Med Rehabil* 1972; 53:403–06.
45. Phillips MF, Smith PE, Carroll N, Edwards RH, Calverley PM. Nocturnal oxygenation and prognosis in Duchenne muscular dystrophy. *Am J Respir Crit Care Med* 1999; 160:198–202.
46. Escolar DM, Buyse G, Henricson E, et al. CINRG randomized controlled trial of creatine and glutamine in Duchenne muscular dystrophy. *Ann Neurol* 2005; 58:151–55.
47. Cyrulnik SE, Fee RJ, Batchelder A, Kiefel J, Goldstein E, Hinton VJ. Cognitive and adaptive difficulties in young children with Duchenne muscular dystrophy (DMD). *J Int Neuropsychol Soc* 2008; 14:853–61.
48. Maria Sofia Falzarano, Chiara Scotton, Chiara Passarelli and Alessandra Ferlini. Duchenne Muscular Dystrophy: From Diagnosis to Therapy. *Molecules* 2015; 20:18168-18184.
49. Jean K Mah. Current and emerging treatment strategies for Duchenne muscular dystrophy. *Neuropsychiatric Disease and Treatment* 2016;12 1795–1807
50. Merlini L, Cicognani A, Malaspina E, et al. Early prednisone treatment in Duchenne muscular dystrophy. *Muscle Nerve* 2003; 27:222-7.

